Related Experiment Video
Updated: Jun 9, 2025
14:21
Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
18.3K
PET Mapping of Receptor Occupancy Using Joint Direct Parametric Reconstruction.
IEEE Transactions on Bio-Medical Engineering
|October 24, 2024
Summary
This study introduces a new PET imaging method for accurately measuring drug receptor occupancy in the brain. The novel framework improves estimations, especially in low-binding regions, aiding CNS drug development.
Area of Science:
- Neuroimaging
- Pharmacology
- Biophysics
Background:
- Positron Emission Tomography (PET) neuroimaging is crucial for central nervous system (CNS) drug development.
- Conventional receptor occupancy (RO) estimation methods using PET have limitations, particularly in low receptor density regions, due to noise in dynamic scan data and separate analysis.
Purpose of the Study:
- To evaluate a novel joint direct parametric reconstruction framework for estimating brain receptor occupancy (RO) and kinetic parameters from PET scans.
- To improve the accuracy and precision of RO estimation, especially in challenging low-binding regions.
Main Methods:
- A joint direct parametric reconstruction framework was developed, integrating regularization on RO maps and alternating optimization.
- The method directly estimates RO distributions from pairs of baseline and post-drug injection dynamic PET scans.
Main Results:
- Simulations showed quantitative improvements in accuracy and precision of occupancy estimation compared to conventional methods.
- Preclinical in-vivo experiments using 11C-MK-6884 demonstrated enhanced RO estimation in muscarinic acetylcholine receptor 4 positive allosteric modulator studies.
Conclusions:
- The proposed joint direct estimation framework significantly enhances RO estimation over traditional methods, particularly in intermediate to low-binding brain regions.
- This advanced PET imaging approach holds potential for facilitating the evaluation of new CNS drug candidates.
